NASDAQ$ARVN
Arvinas Inc. · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Arvinas reported its Q4 2025 earnings, with a significant increase in collaboration revenue and a narrower net loss compared to the previous year.
Arvinas delivered a strong fourth quarter in 2025, primarily driven by a substantial increase in collaboration revenue. The company reported a net loss of $45.3 million, a significant improvement from the $70.1 million net loss in the same period last year. Research and development expenses remained a major investment, reflecting ongoing clinical programs.
- Collaboration revenue surged to $35.2 million in Q4 2025, up from $10.5 million in Q4 2024.
- Net loss narrowed to $45.3 million in Q4 2025, a considerable improvement from $70.1 million in Q4 2024.
- Research and development expenses were $65.8 million, indicating continued investment in pipeline development.
- General and administrative expenses decreased slightly to $18.5 million from $19.2 million in the prior year quarter.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$35.2M
Revenue by segment
Arvinas · $30.3M total across 1 segment · Q3 2022
- Collaboration Revenue$30.3M+225.8%100.0%
Forward guidance
Arvinas anticipates continued progress in its clinical programs and expects to maintain a strong financial position, supported by existing cash and potential collaboration milestones.
Tailwinds
- Strong cash position of $650 million expected to fund operations into 2028.
- Advancement of multiple clinical-stage programs, including lead candidates in oncology.
- Potential for additional collaboration revenue and milestone payments.
- Focus on strategic partnerships to expand pipeline and market reach.
- Continued investment in innovative protein degradation therapies.
Headwinds
- Ongoing significant research and development expenses.
- Uncertainty regarding clinical trial outcomes and regulatory approvals.
- Reliance on collaboration partners for certain program developments.
- Potential for increased competition in the oncology therapeutic area.
- Market and economic conditions could impact funding and operational costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro